Our business model contemplates alliances and joint ventures with companies that have the capability and interest in co-development of new products and/or have the regional or global market presence to successfully promote our products.

ALGENEX aims to participate in well defined market segments of:

• Human and veterinary vaccines
• Diagnostic reagents for human and veterinary use
• Development and supply of high quality recombinant proteins at competitive costs

ALGENEX has the ability to rapidly scale up its production capacity for diagnostic proteins and the flexibility to increase the vaccine production yield when necessary. Due to our efficient technology, ALGENEX could become the preferred partner to companies seeking to develop new vaccines and diagnostics, to extend or consolidate their current market presence or to reduce their manufacturing cost within the scope of our Technology Platform and R&D focus.

.